Myocardial dysfunction during sepsis: Epidemiology, prognostic significance and treatment;Disfunzione miocardica in corso di sepsi: Epidemiologia, significato prognostico e trattamento

Giornale Italiano di Cardiologia

Volumn 12, Issue 12, 2011, Pages 804-814

  Paoli, Giorgia ^a   Valente, Serafina ^b   Ardissino, Diego ^a   Gensini, Gian Franco ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Myocardial dysfunction; Sepsis; Septic shock

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; ENDOTOXIN; NITRIC OXIDE;

ANTIBIOTIC THERAPY; CARDIOMEGALY; CLINICAL FEATURE; CORONARY ARTERY BLOOD FLOW; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; EPIDEMIC; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; TREATMENT INDICATION;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; COMBINED MODALITY THERAPY; COMPLEMENT C5A; COUNTERPULSATION; CYTOKINES; ENDOTHELINS; ENDOTOXINS; HUMANS; IMMUNOTHERAPY; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; NITRIC OXIDE; PROGNOSIS; SEPSIS; TOLL-LIKE RECEPTOR 4;

EID: 84855840281     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: 10.1714/996.10825     Document Type: Review

References (104)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10. (Pubitemid 32641789)
2. Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007;33:606-18. (Pubitemid 46474888)
3. Moerer O, Plock E, Mgbor U, et al. A German national prevalence study on the cost of intensive care: an evaluation from 51 intensive care units. Crit Care 2007;11: R69.
4. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8. (Pubitemid 36523666)
5. Moranville MP, Mieure KD, Santayana EM. Evaluation and management of shock states: hypovolemic, distributive, and cardiogenic shock. J Pharm Pract 2011;24:44-60.
6. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-42. (Pubitemid 20242299)
7. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6. (Pubitemid 36444440)
8. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984;100:483-90. (Pubitemid 14126735)
9. Jafri SM, Lavine S, Field BE, Bahorozian MT, Carlson RW. Left ventricular diastolic function in sepsis. Crit Care Med 1990; 18:709-14. (Pubitemid 20216234)
10. Munt B, Jue J, Gin K, Fenwick J, Tweeddale M. Diastolic filling in human severe sepsis: an echocardiographic study. Crit Care Med 1998;26:1829-33. (Pubitemid 28527694)
11. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 1997;23:553-60. (Pubitemid 27263068)
12. Dhainaut JF, Lanore JJ, de Gournay JM, et al. Right ventricular dysfunction in patients with septic shock. Intensive Care Med 1988;14(Suppl 2):488-91.
13. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990; 97:126-31. (Pubitemid 20023505)
14. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-7. (Pubitemid 19193802)
15. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 1977;296:476-80. (Pubitemid 8038309)
16. Lambermont B, Ghuysen A, Kolh P, et al. Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res 2003;59:412-8. (Pubitemid 37272035)
17. Charpentier J, Luyt CE, Fulla Y, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004;32:660-5. (Pubitemid 38340060)
18. Groeneveld AB, Nauta JJ, Thijs LG. Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med 1988;14:141-7.
19. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parrillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987; 15:923-9. (Pubitemid 18055700)
20. Kumar A, Schupp E, Bunnell E, Ali A, Milcarek B, Parrillo JE. Cardiovascular response to dobutamine stress predicts outcome in severe sepsis and septic shock. Crit Care 2008;12:R35.
21. Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds RM, Bennett ED. A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock. Crit Care Med 1999;27:2361-6.
22. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000;46:650-7. (Pubitemid 30318420)
23. Metha NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004; 95:13-7. (Pubitemid 38670466)
24. Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003;41: 2004-9. (Pubitemid 36677123)
25. Abraham E, Laterre PF, Garg R, et al.; Administration of Drotrecogin Alfa (Activated) in Early Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41. (Pubitemid 41362701)
26. McLean AS, Huang SJ, Hyams S, et al. Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007;35:1019-26. (Pubitemid 46598950)
27. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettila V; FINNSEPSIS Study Group. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007;35:1277-83. Studio prospettico osservazionale di coorte che per la prima volta ha mostrato su un'ampia casistica il peso prognostico del peptide natriuretico cerebrale nella stratificazione dei pazienti con sepsi. (Pubitemid 46642654)
28. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006;129:1349-66.
29. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation 1986;73:637-44. (Pubitemid 16081421)
30. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987;75:533-41. (Pubitemid 17026042)
31. Spronk PE, Zandstra DF, Ince C. Bench-to- bedside review: sepsis is a disease of the microcirculation. Crit Care 2004;8:462-8. (Pubitemid 40073681)
32. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985;76: 1539-53. Da questo studio pionieristico emerge che il siero dei pazienti affetti da sepsi contiene genericamente "sostanze" in grado di deprimere la contrattilità miocitaria in vitro. (Pubitemid 16193573)
33. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271: 1836-43. (Pubitemid 24169697)
34. Hoffmann JN, Werdan K, Hartl WH, Jochum M, Faist E, Inthorn D. Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock 1999;12: 174-80.
35. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998;30: 215-23. (Pubitemid 28116301)
36. Hunter JD, Doddi M. Sepsis and the heart. Br J Anaesth 2010;104:3-11.
37. Merx MW, Weber C. Sepsis and the heart. Circulation 2007;116:793-802. (Pubitemid 47255997)
38. Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen H, Kubes P. Immune cell toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 2004;95:700-7. (Pubitemid 39331930)
39. Rassaf T, Poll LW, Brouzos P, et al. Positive effects of nitric oxide on left ventricular function in humans. Eur Heart J 2006; 27:1699-705. (Pubitemid 44025358)
40. Brady AJ, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992; 263(6 Pt 2):H1963-H1966. (Pubitemid 23030755)
41. Balligand JL, Ungureanu D, Kelly RA, et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993;91:2314-9. (Pubitemid 23141511)
42. Fink MP. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin 2001;17:219-37. (Pubitemid 32163188)
43. Hayes MA, Timmins AC, Yau EH, Palazzo M, Watson D, Hinds CJ. Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. Crit Care Med 1997;25:926-36. (Pubitemid 27264235)
44. Mela L, Bacalzo LV Jr, Miller LD. Defective oxidative metabolism of rat liver mitochondria in hemorrhagic and endotoxin shock. Am J Physiol 1971;220:571-7.
45. Cowley RA, Mergner WJ, Fisher RS, Jones RT, Trump BF. The subcellular pathology of shock in trauma patients: studies using the immediate autopsy. Am Surg 1979; 45:255-69. (Pubitemid 9147648)
46. Morikawa S, Inubushi T, Takahashi K, Ishii H, Ozawa K. Gluconeogenesis and phosphoenergetics in rat liver during endotoxemia. J Surg Res 1998;74:179-86. (Pubitemid 28270368)
47. Levy RJ. Mitochondrial dysfunction, bioenergetic impairment, and metabolic down-regulation in sepsis. Shock 2007;28: 24-8. (Pubitemid 46956458)
48. Crouser ED. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004;4: 729-41. (Pubitemid 39646818)
49. Exline MC, Crouser ED. Mitochondrial mechanisms of sepsis-induced organ failure. Front Biosci 2008;13:5030-41. (Pubitemid 351599656)
50. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360:219-23. (Pubitemid 34804650)
51. Brealey D, Karyampudi S, Jacques TS, et al. Mitochondrial dysfunction in a longterm rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004;286:R491-R497. (Pubitemid 38252613)
52. Crouser ED, Julian MW, Blaho DV, Pfeiffer DR. Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit Care Med 2002;30: 276-84. (Pubitemid 34158107)
53. Buerke U, Carter JM, Schlitt A, et al. Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock 2008;29:497-503. (Pubitemid 351416804)
54. Sharshar T, Gray F, Lorin de la Grandmaison G, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003;362: 1799-805. (Pubitemid 37494758)
55. Annane D, Trabold F, Sharshar T, et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 1999; 160:458-65. (Pubitemid 29380658)
56. Piepoli M, Garrard CS, Kontoyannis DA, Bernardi L. Autonomic control of the heart and peripheral vessels in human septic shock. Intensive Care Med 1995;21:112-9.
57. Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Muller B. Circulating precursor levels of endothelin- 1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007;14:345-51.
58. Yang LL, Gros R, Kabir MG, et al. Conditional cardiac overexpression of endothelin- 1 induces inflammation and dilated cardiomyopathy in mice. Circulation 2004;109: 255-61. (Pubitemid 38114148)
59. Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, Yoshida M. Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol 1994;84:189-95.
60. Smedegard G, Cui LX, Hugli TE. Endotoxin- induced shock in the rat. A role for C5a. Am J Pathol 1989;135:489-97. (Pubitemid 19246207)
61. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999;5:788-92. (Pubitemid 29318613)
62. Guo RF, Riedemann NC, Bernacki KD, et al. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J 2003;17:1889-91.
63. Niederbichler AD, Hoesel LM, Westfall MV, et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 2006;203:53-61. (Pubitemid 43139645)
64. Hoesel LM, Niederbichler AD, Schaefer J, et al. C5a-blockade improves burn-induced cardiac dysfunction. J Immunol 2007; 178:7902-10. (Pubitemid 46898062)
65. Farquhar I, Martin CM, Lam C, Potter R, Ellis CG, Sibbald WJ. Decreased capillary density in vivo in bowel mucosa of rats with normotensive sepsis. J Surg Res 1996;61: 190-6. (Pubitemid 26066050)
66. Groeneveld AB, van Lambalgen AA, van den Bos GC, Bronsveld W, Nauta JJ, Thijs LG. Maldistribution of heterogeneous coronary blood flow during canine endotoxin shock. Cardiovasc Res 1991;25:80-8.
67. Lam C, Tyml K, Martin C, Sibbald W. Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest 1994;94:2077-83. (Pubitemid 24348249)
68. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993;27:1380-2. (Pubitemid 23250924)
69. Aird WC. Endothelium as an organ system. Crit Care Med 2004;32(5 Suppl): S271-S279.
70. Trzeciak S, Cinel I, Dellinger RP, et al.; Microcirculatory Alterations in Resuscitation and Shock (MARS) Investigators. Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med 2008;15: 399-413.
71. Yano K, Liaw PC, Mullington JM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006;203:1447-58. (Pubitemid 43877607)
72. Condon MR, Kim JE, Deitch EA, Machiedo GW, Spolarics Z. Appearance of an erythrocyte population with decreased deformability and hemoglobin content following sepsis. Am J Physiol Heart Circ Physiol 2003;284:H2177-H2184. (Pubitemid 36622430)
73. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004;32:1825-31. (Pubitemid 39202356)
74. Trzeciak S, Dellinger RP, Parrillo JE, et al.; Microcirculatory Alterations in Resuscitation and Shock Investigators. Early micro-circulatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 2007;49:88-98.
75. Vincent JL, De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care 2005; 9(Suppl 4):S9-S12. (Pubitemid 41498526)
76. Doerschug KC, Delsing AS, Schmidt GA, Haynes WG. Impairments in microvascular reactivity are related to organ failure in human sepsis. Am J Physiol Heart Circ Physiol 2007;293:H1065-H1071. (Pubitemid 47254206)
77. Rossi MA, Celes MR, Prado CM, Saggioro FP. Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. Shock 2007;27:10-8.
78. Shepherd RE, Lang CH, McDonough KH. Myocardial adrenergic responsiveness after lethal and nonlethal doses of endotoxin. Am J Physiol 1987;252(2 Pt 2):H410-H416.
79. Böhm M, Kirchmayr R, Gierschik P, Erdmann E. Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure. Am J Med 1995;98:183-6.
80. Levy RJ, Piel DA, Acton PD, et al. Evidence of myocardial hibernation in the septic heart. Crit Care Med 2005;33:2752-6. (Pubitemid 41816407)
81. Rivers E, Nguyen B, Havstad S, et al.; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-77. Questo studio clinico monocentrico randomizzato ha dimostrato che nei pazienti con sepsi severa/shock settico una precoce e sistematica rianimazione a step subordinata al raggiungimento di precisi obiettivi clinici determina una riduzione della mortalità del 16%.
82. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327. Importante documento di consenso internazionale che riassume la terapia consolidata e fornisce raccomandazioni e livelli di evidenza sui molteplici approcci terapeutici che devono essere messi in atto in corso di sepsi.
83. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56. (Pubitemid 38669207)
84. Brunkhorst FM, Engel C, Bloos F, et al.; German Competence Network Sepsis (Sep- Net). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
85. De Backer D, Biston P, Devriendt J, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362: 779-89.
86. Annane D, Vignon P, Renault A, et al.; CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370:676-84. (Pubitemid 47299251)
87. Russell JA, Walley KR, Singer J, et al.; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87. (Pubitemid 351397087)
88. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5. (Pubitemid 27097820)
89. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003;107:2313-9. (Pubitemid 36578501)
90. Russell JA, Walley KR, Gordon AC, et al.; Dieter Avers for the Vasopressin and Septic Shock Trial Investigators. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-8.
91. Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010;36:83-91.
92. Jardin F, Sportiche M, Bazin M, Bourokba A, Margairaz A. Dobutamine: a hemodynamic evaluation in human septic shock. Crit Care Med 1981;9:329-32.
93. Overgaard CB, Dzavík V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 2008;118:1047-56.
94. Powell BP, De Keulenaer BL. Levosimendan in septic shock: a case series. Br J Anaesth 2007;99:447-8. (Pubitemid 47316410)
95. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005;31: 638-44. (Pubitemid 40684980)
96. Pribble CG, Shaddy RE. Intra-aortic balloon counterpulsation in newborn lambs infected with group B streptococcus. ASAIO Trans 1991;37:33-7.
97. Roberts AJ, Hoover EL, Alonso DR, et al. Prolonged intraaortic balloon pumping in klebsiella-induced hypodynamic shock: cardiopulmonary, hematological, metabolic, and pathological observations. Ann Thorac Surg 1979;28:73-86. (Pubitemid 9223768)
98. Mercer D, Doris P, Salerno TA. Intraaortic balloon counterpulsation in septic shock. Can J Surg 1981;24:643-5. (Pubitemid 12244313)
99. Foster ED, Subramanian VA, Hechtman HB, Berger RL, Vito L. Response to intra- aortic balloon pumping. Am J Surg 1975;129:464-71.
100. Solomon SB, Minneci PC, Deans KJ, et al. Effects of intra-aortic balloon counter-pulsation in a model of septic shock. Crit Care Med 2009;37:7-18.
101. Schmittinger CA, Dünser MW, Haller M, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008;12: R99.
102. Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004;109: 2560-5. (Pubitemid 38720557)
103. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001;103: 973-80. (Pubitemid 32183803)
104. Konrad D, Oldner A, Rossi P, Wanecek M, Rudehill A, Weitzberg E. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock. Crit Care Med 2004;32:1192-9. (Pubitemid 38620990)